Amgen, Inc. (AMGN) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1150325,
    "name": "Amgen, Inc.",
    "stock_name": "Amgen, Inc.",
    "full_name": "Amgen, Inc.",
    "name_url": "stocks-analysis/amgen-inc",
    "exchange": 210,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "340.16",
    "chg": 1.8,
    "chgp": "0.53%",
    "dir": 1,
    "prev_price": "338.36",
    "mcapval": "150,843.62",
    "mcap": "Large Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2305,
    "indexname": "S&P 500",
    "isin": "US0311621009",
    "curr_date": "Dec 04",
    "curr_time": "",
    "bse_nse_vol": "7.39 M",
    "exc_status": "Active",
    "traded_date": "Dec 04, 2025",
    "traded_date_str": "2025 12 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/amgen-inc-1150325-210&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Amgen, Inc. Experiences Revision in Stock Evaluation Amid Competitive Market Landscape",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/amgens-valuation-grade-downgraded-from-attractive-to-fair-amid-price-fluctuations-3667012",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/AmgenInc_valuationdot_3667012.png",
        "date": "2025-11-03 15:28:03",
        "description": "Amgen, Inc. has recently adjusted its valuation metrics, with a P/E ratio of 22 and a Price to Book Value of 25.15. The company demonstrates strong financial health, evidenced by a high ROE of 116.13% and a PEG ratio of 0.27, amidst a competitive pharmaceutical landscape."
      },
      {
        "title": "Amgen, Inc. Experiences Revision in Stock Evaluation Amid Market Dynamics",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/amgen-inc-technical-trend-shifts-from-sideways-to-mildly-bearish-amid-stock-decline-3651977",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/AmgenInc_technicaldot_3651977.png",
        "date": "2025-10-28 15:05:28",
        "description": "Amgen, Inc. has recently revised its evaluation amid current market dynamics, with its stock price at $291.16. The company has seen a 7.77% decline over the past year, underperforming compared to the S&P 500. Despite a year-to-date return of 11.71%, Amgen faces challenges in competitive performance."
      },
      {
        "title": "Is Amgen, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-amgen-inc-technically-bullish-or-bearish-3651246",
        "imagepath": "",
        "date": "2025-10-28 11:38:36",
        "description": "As of 24 October 2025, the technical trend for Amgen, Inc. has changed from sideways to mildly bearish. The current technical stance is mildly bearish, driven by the daily moving averages and the KST, which are both bearish. The MACD shows a conflicting mildly bullish signal on the weekly chart but is mildly bearish on the monthly chart. The Dow Theory indicates a mildly bullish stance on the weekly timeframe but is also mildly bearish monthly. \n\nIn terms of performance, Amgen's returns have lagged behind the S&P 500 across multiple periods, with a year-to-date return of 11.94% compared to the S&P 500's 15.47%, and a one-year return of -7.58% versus the S&P 500's 16.90%. Overall, the mixed signals suggest caution in the current market environment...."
      },
      {
        "title": "Is Amgen, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-amgen-inc-technically-bullish-or-bearish-3647699",
        "imagepath": "",
        "date": "2025-10-27 11:49:45",
        "description": "As of 24 October 2025, the technical trend for Amgen, Inc. has changed from sideways to mildly bearish. The weekly MACD is mildly bullish, but the monthly MACD is mildly bearish, indicating mixed signals. The daily moving averages are mildly bearish, and the KST is bearish on both weekly and monthly timeframes. The Dow Theory shows a mildly bullish stance weekly but is bearish monthly. Overall, the indicators suggest a mildly bearish sentiment.\n\nIn terms of performance, Amgen's returns have lagged behind the S&P 500 across multiple periods, notably with a 1-year return of -7.58% compared to the S&P 500's 16.90%, and a 3-year return of 11.65% versus 78.85% for the index...."
      },
      {
        "title": "Is Amgen, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-amgen-inc-technically-bullish-or-bearish-3646236",
        "imagepath": "",
        "date": "2025-10-26 11:24:30",
        "description": "As of 24 October 2025, the technical trend for Amgen, Inc. has changed from sideways to mildly bearish. The weekly MACD indicates a mildly bullish stance, but the monthly MACD and KST are both mildly bearish. The daily moving averages also reflect a mildly bearish position. The Dow Theory shows a mildly bullish signal on the weekly timeframe but is bearish on the monthly. Overall, the indicators suggest a bearish sentiment, particularly in the longer time frames.\n\nIn terms of performance, Amgen's returns have been weaker compared to the S&P 500 across multiple periods, with a 1-year return of -7.58% versus the S&P 500's 16.90%, and a 3-year return of 11.65% compared to 78.85% for the index...."
      },
      {
        "title": "Amgen's Valuation Shift Signals Potential Growth Opportunities Amid Strong Financial Metrics",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/amgen-upgraded-to-strong-buy-as-valuation-grade-improves-to-attractive-3640166",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/AmgenInc_mojoScore_3640166.png",
        "date": "2025-10-23 15:36:42",
        "description": "Amgen, Inc. has recently experienced a change in its valuation grade, indicating a shift in market perception. Key financial metrics reveal a strong industry position, with a P/E ratio of 22 and a PEG ratio of 0.27, alongside significant operating cash flow and robust management efficiency."
      },
      {
        "title": "Is Amgen, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-amgen-inc-overvalued-or-undervalued-3637363",
        "imagepath": "",
        "date": "2025-10-21 12:00:47",
        "description": "As of 17 October 2025, the valuation grade for Amgen, Inc. moved from expensive to attractive, indicating a shift towards a more favorable assessment. The company appears undervalued based on its current metrics, with a P/E ratio of 22, a PEG ratio of 0.27, and an EV to EBITDA ratio of 14.13, suggesting that the stock is priced lower relative to its growth potential compared to peers. \n\nIn comparison to its peer Gilead Sciences, Inc., which has a P/E of 15.53 and an EV to EBITDA of 11.81, Amgen's valuation metrics reflect a more attractive investment opportunity. Additionally, Amgen's return over the past year shows a decline of 7.01%, contrasting with the S&P 500's gain of 14.08%, which highlights the potential for recovery given its current valuation. Overall, Amgen's strong ROE of 116.13% and solid dividend yield of 3.18% further support the case for its undervaluation...."
      },
      {
        "title": "Amgen, Inc. Experiences Revision in Its Stock Evaluation Amid Market Dynamics",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/amgens-valuation-grade-changes-from-expensive-to-attractive-amid-stock-price-increase-3640471",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/AmgenInc_valuationdot_3640471.png",
        "date": "2025-10-20 15:27:48",
        "description": "Amgen, Inc. has recently adjusted its valuation, showcasing a P/E ratio of 22 and a price-to-book value of 25.15. The company demonstrates strong financial metrics, including a high return on equity of 116.13% and a dividend yield of 3.18%, while facing market challenges reflected in its one-year return."
      },
      {
        "title": "Is Amgen, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-amgen-inc-overvalued-or-undervalued-3631774",
        "imagepath": "",
        "date": "2025-10-19 11:56:22",
        "description": "As of 17 October 2025, Amgen, Inc. has moved from expensive to attractive, indicating a significant shift in its valuation outlook. The company appears undervalued based on its current metrics, particularly with a P/E ratio of 22, a PEG ratio of 0.27, and an EV to EBITDA of 14.13. In comparison to its peer Gilead Sciences, which has a P/E of 15.53 and is deemed very expensive, Amgen's valuation stands out as more favorable.\n\nThe recent performance of Amgen's stock has also been noteworthy, with a year-to-date return of 14.64%, slightly outperforming the S&P 500's return of 13.30% in the same period. However, over the longer term, Amgen's 1-year return of -7.01% lags behind the S&P 500's 14.08%, suggesting some volatility. Overall, the combination of attractive valuation ratios and competitive positioning among peers supports the conclusion that Amgen is currently undervalued...."
      }
    ],
    "total": 21,
    "sid": "1150325",
    "stock_news_url": "https://www.marketsmojo.com/news/amgen-inc-1150325"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Amgen, Inc. Experiences Revision in Stock Evaluation Amid Competitive Market Landscape

2025-11-03 15:28:03

Amgen, Inc. has recently adjusted its valuation metrics, with a P/E ratio of 22 and a Price to Book Value of 25.15. The company demonstrates strong financial health, evidenced by a high ROE of 116.13% and a PEG ratio of 0.27, amidst a competitive pharmaceutical landscape.

Amgen, Inc. Experiences Revision in Stock Evaluation Amid Market Dynamics

2025-10-28 15:05:28

Amgen, Inc. has recently revised its evaluation amid current market dynamics, with its stock price at $291.16. The company has seen a 7.77% decline over the past year, underperforming compared to the S&P 500. Despite a year-to-date return of 11.71%, Amgen faces challenges in competitive performance.

Is Amgen, Inc. technically bullish or bearish?

2025-10-28 11:38:36

As of 24 October 2025, the technical trend for Amgen, Inc. has changed from sideways to mildly bearish. The current technical stance is mildly bearish, driven by the daily moving averages and the KST, which are both bearish. The MACD shows a conflicting mildly bullish signal on the weekly chart but is mildly bearish on the monthly chart. The Dow Theory indicates a mildly bullish stance on the weekly timeframe but is also mildly bearish monthly. In terms of performance, Amgen's returns have lagged behind the S&P 500 across multiple periods, with a year-to-date return of 11.94% compared to the S&P 500's 15.47%, and a one-year return of -7.58% versus the S&P 500's 16.90%. Overall, the mixed signals suggest caution in the current market environment....

Is Amgen, Inc. technically bullish or bearish?

2025-10-27 11:49:45

As of 24 October 2025, the technical trend for Amgen, Inc. has changed from sideways to mildly bearish. The weekly MACD is mildly bullish, but the monthly MACD is mildly bearish, indicating mixed signals. The daily moving averages are mildly bearish, and the KST is bearish on both weekly and monthly timeframes. The Dow Theory shows a mildly bullish stance weekly but is bearish monthly. Overall, the indicators suggest a mildly bearish sentiment. In terms of performance, Amgen's returns have lagged behind the S&P 500 across multiple periods, notably with a 1-year return of -7.58% compared to the S&P 500's 16.90%, and a 3-year return of 11.65% versus 78.85% for the index....

Is Amgen, Inc. technically bullish or bearish?

2025-10-26 11:24:30

As of 24 October 2025, the technical trend for Amgen, Inc. has changed from sideways to mildly bearish. The weekly MACD indicates a mildly bullish stance, but the monthly MACD and KST are both mildly bearish. The daily moving averages also reflect a mildly bearish position. The Dow Theory shows a mildly bullish signal on the weekly timeframe but is bearish on the monthly. Overall, the indicators suggest a bearish sentiment, particularly in the longer time frames. In terms of performance, Amgen's returns have been weaker compared to the S&P 500 across multiple periods, with a 1-year return of -7.58% versus the S&P 500's 16.90%, and a 3-year return of 11.65% compared to 78.85% for the index....

Amgen's Valuation Shift Signals Potential Growth Opportunities Amid Strong Financial Metrics

2025-10-23 15:36:42

Amgen, Inc. has recently experienced a change in its valuation grade, indicating a shift in market perception. Key financial metrics reveal a strong industry position, with a P/E ratio of 22 and a PEG ratio of 0.27, alongside significant operating cash flow and robust management efficiency.

Is Amgen, Inc. overvalued or undervalued?

2025-10-21 12:00:47

As of 17 October 2025, the valuation grade for Amgen, Inc. moved from expensive to attractive, indicating a shift towards a more favorable assessment. The company appears undervalued based on its current metrics, with a P/E ratio of 22, a PEG ratio of 0.27, and an EV to EBITDA ratio of 14.13, suggesting that the stock is priced lower relative to its growth potential compared to peers. In comparison to its peer Gilead Sciences, Inc., which has a P/E of 15.53 and an EV to EBITDA of 11.81, Amgen's valuation metrics reflect a more attractive investment opportunity. Additionally, Amgen's return over the past year shows a decline of 7.01%, contrasting with the S&P 500's gain of 14.08%, which highlights the potential for recovery given its current valuation. Overall, Amgen's strong ROE of 116.13% and solid dividend yield of 3.18% further support the case for its undervaluation....

Amgen, Inc. Experiences Revision in Its Stock Evaluation Amid Market Dynamics

2025-10-20 15:27:48

Amgen, Inc. has recently adjusted its valuation, showcasing a P/E ratio of 22 and a price-to-book value of 25.15. The company demonstrates strong financial metrics, including a high return on equity of 116.13% and a dividend yield of 3.18%, while facing market challenges reflected in its one-year return.

Is Amgen, Inc. overvalued or undervalued?

2025-10-19 11:56:22

As of 17 October 2025, Amgen, Inc. has moved from expensive to attractive, indicating a significant shift in its valuation outlook. The company appears undervalued based on its current metrics, particularly with a P/E ratio of 22, a PEG ratio of 0.27, and an EV to EBITDA of 14.13. In comparison to its peer Gilead Sciences, which has a P/E of 15.53 and is deemed very expensive, Amgen's valuation stands out as more favorable. The recent performance of Amgen's stock has also been noteworthy, with a year-to-date return of 14.64%, slightly outperforming the S&P 500's return of 13.30% in the same period. However, over the longer term, Amgen's 1-year return of -7.01% lags behind the S&P 500's 14.08%, suggesting some volatility. Overall, the combination of attractive valuation ratios and competitive positioning among peers supports the conclusion that Amgen is currently undervalued....

View All News